◀ Back to ICAM1

CHUK — ICAM1

Text-mined interactions from Literome

Huang et al., Carcinogenesis 2004 (Neoplasm Invasiveness) : ICAM-1 promoter activities induced by the over-expression of wild-type NF-kappaB inducing kinase and IkappaB kinase beta (IKKbeta) were also inhibited by both compounds
Catley et al., Br J Pharmacol 2005 (Asthma) : Similarly, IKK beta ( KA ) and I kappa B alpha delta N overexpression also inhibited IL-1beta- and TNF alpha dependent increases in ICAM-1 , IL-8 and GM-CSF in addition to IL-1beta mediated increases in cyclooxygenase-2 expression, whereas IKK alpha ( KM ) overexpression had little effect on these outputs
Uchihara et al., Int J Cancer 2006 (Hodgkin Disease) : Coexpression of IkappaB, IKK , NIK and TRAF dominant negative constructs with CD30 inhibited CD30 induced activation of ICAM-1 promoter, suggesting that CD30 induces ICAM-1 via NF-kappaB signalling
Catley et al., Mol Pharmacol 2006 (Pulmonary Disease, Chronic Obstructive) : As observed above, ICAM-1 , IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was reduced by the IKK inhibitors ... As observed above, ICAM-1 , IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was reduced by the IKK inhibitors
Mukherjee et al., J Immunol 2007 : This study further addressed that IkappaB kinase (IKK) , a phosphorylation dependent regulator of NF-kappaB, plays an important regulatory role in the TNF-alpha mediated induction of the inflammatory cell surface molecule ICAM-1